San Francisco, CA, United States of America

Gloria Brattich

USPTO Granted Patents = 2 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2022-2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Gloria Brattich: Innovator in Antibody Development

Introduction

Gloria Brattich is a prominent inventor based in San Francisco, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic use. With a total of 2 patents, her work focuses on innovative solutions for treating various disorders, including cancer.

Latest Patents

Brattich's latest patents include the development of B7-H4 antibodies and methods of use thereof. These patents provide antibodies and antigen-binding fragments that specifically bind to human B7-H4, with potential applications in increasing T cell proliferation and interferon-gamma production. Additionally, these antibodies can deplete B7-H4 expressing cells via ADCC activity, offering promising methods for treating disorders such as cancer.

Career Highlights

Gloria Brattich is currently associated with Five Prime Therapeutics, Inc., where she continues to advance her research in antibody development. Her innovative work has positioned her as a key figure in the biotechnology sector, contributing to the understanding and treatment of complex diseases.

Collaborations

Throughout her career, Brattich has collaborated with notable colleagues, including Charles Kaplan and Derrick Houser. These partnerships have enhanced her research efforts and expanded the impact of her inventions.

Conclusion

Gloria Brattich's contributions to the field of biotechnology through her innovative patents and collaborations highlight her role as a leading inventor. Her work in developing B7-H4 antibodies represents a significant advancement in therapeutic strategies for cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…